Replies to post #248559 on NorthWest Biotherapeutics Inc (NWBO)

[survivor1x]

Define "progression". The Fat OS tail will help us define progression in this trial

[Umibe5690]

I am hopeful that overall PFS is as well. But, overall PFS could fail to achieve the 4 month end point, however,it is possible that a sub-group like M+ and/or MES could do well. Or it could be demonstrated that although the PFS end-point was not met, the vaccine was able, in time, to dramatically slow progression thus contributing to enhanced OS. It does not necessarily follow that a thick OS tail, ipso facto, requires a fat PFS tail. But I am hoping for it. As I said in many previous posts, the ball game is played on the long tail. How long is it? How thick is it? What is its composition? Failure to achieve the original primary and secondary endpoints may not be a bad thing and, as I have suggested with a proper explanation, turn a seemingly bad thing into a good thing. I am reasonably confident that the tail will tell the tale. JMHO

GLTA.